Researchers at the Icahn School of Medicine at Mount Sinai have discovered how genetics can affect the success of venetoclax, ...

Johnson & Johnson (J&J) has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies ...

Researchers at the Icahn School of Medicine at Mount Sinai have discovered how genetics can affect the success of venetoclax, ...

A ground breaking study mapping the immune microenvironment in Multiple Myeloma identifies critical immune changes and ...

Tyler Sandahl, PharmD, of Mayo Clinic, and Michael Byrne, DO, of Tennessee Oncology, discuss practical advice for bringing ...

Cesar Rodriguez, MD, discussed several key aspects of talquetamab use in the treatment of relapsed/refractory multiple ...

A treatment approach harnessing bispecific antibodies to target cancerous cells unlocks new possibilities for patients, says ...

Biotech HaemaLogiX – which counts former health minister Greg Hunt as a director – is preparing a 2025 ASX listing, as it ...

During a Case-Based Roundtable® event, Saad Z. Usmani, MD, FACP, MBA, discussed quality of life and the future with CAR ...

The study compared CARVYKTI's efficacy and safety against standard-of-care regimens in patients with multiple myeloma.

US FDA accepts for review GSK’s Blenrep combinations for the treatment of relapsed/refractory multiple myeloma: London, UK Tuesday, November 26, 2024, 09:00 Hrs [IST] GSK plc an ...

Patients with relapsed/refractory multiple myeloma could benefit from repeat treatment with drugs their disease has previously been refractory to. Read more.